Jeffrey Testani, MD, MTR
Professor of Medicine (Cardiovascular Medicine)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director of Heart Failure Research, Cardiovascular Medicine
Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Contact Info
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director of Heart Failure Research, Cardiovascular Medicine
Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Contact Info
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director of Heart Failure Research, Cardiovascular Medicine
Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Contact Info
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
About
Copy Link
Titles
Professor of Medicine (Cardiovascular Medicine)
Director of Heart Failure Research, Cardiovascular Medicine; Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Biography
My clinical training is as an advanced heart failure physician with formal research training in patient oriented translational research. My research program is supported by NIH and investigator-initiated industry sources and uses techniques of both translational and clinical research to further the mechanistic understanding of cardiac-renal interactions, fluid and sodium homeostasis, and diuretic resistance. The primary approach of my current research program is prospective mechanistic human studies in heart failure and kidney disease patients, for which we have established extensive infrastructure. N My lab has extensive expertise in biomarker research has established and maintains an extensive bioassay resource with the capability to determine an extensive range of analytes in human biological samples with complexity ranging from simple serum chemistries to complex analytes such as ultra-trace lithium by inductively coupled plasma mass spectrometry, deuterium concentration by IRMS, high dimension multiplex protein assays, and large and small molecules by liquid chromatography mass spectrometry.
Appointments
Cardiovascular Medicine
ProfessorPrimary
Other Departments & Organizations
- Cardiovascular Medicine
- Heart Failure Program
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Cardiovascular Research Center (YCVRC)
- Yale Medicine
- Yale Ventures
Education & Training
- Fellowship
- Hospital of the University of Pennsylvania (2012)
- MS
- University of Pennsylvania Medical School (2012)
- Research Fellowship
- Hospital of the University of Pennsylvania (2011)
- Fellowship
- Hospital of the University of Pennsylvania (2009)
- Residency
- Hospital of the University of Pennsylvania (2007)
- Internship
- Hospital of the University of Pennsylvania (2005)
- MD
- University of Florida (2004)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0001-5285-0419
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
F. Perry Wilson, MD, MSCE
Veena Rao, PhD
Christopher Maulion, MD
Jeffrey Turner, MD
Dennis G Moledina, MD, PhD, FASN
Harlan Krumholz, MD, SM
Heart Failure
Diuretics
Sodium
Cardio-Renal Syndrome
Kidney Diseases
Publications
2025
Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure: Mechanistic Randomized Controlled Trial.
Rao V, Cox Z, Ivey-Miranda J, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Turner J, Wilson F, Shilpak M, Estrella M, Welling P, Wilcox C, Ellison D, Forbush B, Testani J. Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure: Mechanistic Randomized Controlled Trial. Journal Of The American Society Of Nephrology 2025 PMID: 40938670, DOI: 10.1681/asn.0000000887.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFractional excretion of lithiumDose intensificationDiuretic resistanceDiuretic responseFractional excretionHeart failurePrimary outcomeResistance mechanismsLoop diuretic resistanceAcute heart failureExcretion of lithiumLoop of HenleDiuretic strategyRandomized Controlled TrialsSite of actionPrimary trial outcomeOptimal therapyThiazideScreening visitNatriuresisControlled TrialsPatientsInduced increaseExploratory analysisTherapyEffects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial
Borlaug B, Testani J, Petrie M, Wang Z, Cunningham J, Adams K, Amir O, Bělohlávek J, Bocchi E, Freitas A, Hominal M, Kadokami T, Merkely B, Miller C, Nuñez J, Verma S, Yilmaz M, Oru E, Sam F. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Nature Medicine 2025, 1-9. PMID: 40887551, DOI: 10.1038/s41591-025-03939-6.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEstimated glomerular filtration rateLA reservoir strainLong-acting formHeart failureReservoir strainNT-proBNPKidney functionHuman relaxinRenal serious adverse eventsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptidePhase 2 randomized trialNT-proBNP levelsPreserved Ejection FractionSerious adverse eventsGlomerular filtration rateDouble-blindEjection fractionSecondary endpointsMulticenter trialNatriuretic peptideDecompensated HFpEFLA functionHF hospitalizationAdverse eventsAldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti F, Testani J, Tio M, Pitt B, Butler J. Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases. Journal Of The American College Of Cardiology 2025, 86: 354-373. PMID: 40738563, DOI: 10.1016/j.jacc.2025.06.012.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMineralocorticoid receptor antagonist therapyMineralocorticoid receptor antagonistsChronic kidney diseaseNonsteroidal mineralocorticoid receptor antagonistAldosterone synthase inhibitorsHeart failureAssociated with progressionExcess aldosteronePartial agonistSynthase inhibitorAssociated with progression of chronic kidney diseaseRenin-angiotensin-aldosterone system inhibitorsRenin-angiotensin-aldosterone system activationProgression of chronic kidney diseaseResistant arterial hypertensionMR-mediated effectsEffects of aldosteroneAssociated with elevationAldosterone levelsNeurohormonal activationProspective trialsReceptor antagonistArterial hypertensionAldosterone productionSystem inhibitorsMRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF Differences in Diseases, Drugs, or Both?
Mendonça L, Neves J, Testani J, Zannad F, Ferreira J. MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF Differences in Diseases, Drugs, or Both? JACC Heart Failure 2025, 13: 102514. PMID: 40542794, DOI: 10.1016/j.jchf.2025.102514.Peer-Reviewed Original ResearchCitationsProteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure
Hubbell K, Rao V, Scherzer R, Shlipak M, Ivery‐Miranda J, Bansal N, Cox Z, Testani J, Estrella M. Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure. ESC Heart Failure 2025, 12: 3296-3305. PMID: 40504107, PMCID: PMC12450773, DOI: 10.1002/ehf2.15342.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAcute decompensated heart failureDecompensated heart failureDiuretic responseHeart failureHF rehospitalizationRisk of HF rehospitalizationBiomarker modelAssociated with poor outcomesAssociated with decreased riskAssociated with increased riskAssociated with cardiometabolic diseasesAssociated with mortalityAssociated with rehospitalizationDiuretic resistanceMedian ageResistance cohortClinical factorsPoor outcomeSociodemographic/lifestyle factorsPrognostic toolCombined biomarkersCardiometabolic diseasesPatientsAmbulatory settingMortality riskAssociation of Volume Overload With Kidney Function Outcomes Among Patients With Acute Decompensated Heart Failure
Moises A, Tighiouart H, Testani J, Tuttle M, Banlengchit R, Oka T, Lee K, Ferguson K, Sarnak H, Harding C, Kiernan M, Sarnak M, McCallum W. Association of Volume Overload With Kidney Function Outcomes Among Patients With Acute Decompensated Heart Failure. American Journal Of Kidney Diseases 2025, 86: 324-334.e1. PMID: 40484339, PMCID: PMC12354306, DOI: 10.1053/j.ajkd.2025.03.026.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPulmonary capillary wedge pressureHigh central venous pressureCentral venous pressureAssociation of central venous pressureDecompensated heart failureRisk of dialysisVolume overloadInitiation of dialysisEGFR slopeHeart failureKidney functionDegree of volume overloadLow baseline kidney functionAcute decompensated heart failureRisk factorsAssociated with lower eGFRRight heart catheterizationCox proportional hazards regression modelsCapillary wedge pressureInitial central venous pressureAssociated with increased riskProportional hazards regression modelsBaseline kidney functionKidney function outcomesRestricted cubic splinesSodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study
Biegus J, Iwanek G, Testani J, Zymliński R, Fudim M, Guzik M, Gajewski P, Ponikowski P. Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study. European Journal Of Heart Failure 2025 PMID: 40455066, DOI: 10.1002/ejhf.3708.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAcute heart failureProximal tubular sodium reabsorptionCo-primary endpointsTubular sodium reabsorptionNaCl groupEffective decongestionDiuretic therapyUrine outputSodium reabsorptionHeart failureCumulative dose of furosemideGlucose groupFractional excretion of lithiumDose of furosemideMedian urine outputAbsolute distal reabsorptionVolume replacement therapyExcretion of lithiumSingle-blind studyInfusion of NaClInhibition of proximal tubular sodium reabsorptionFurosemide doseFluid overloadCumulative doseDecongestive effectEvaluation of the Natriuretic Response Prediction Equation using a Race-free Estimated Glomerular Filtration Rate Equation
Cox Z, Rao V, Wrenn J, Collins S, Testani J, Ivey-Miranda J. Evaluation of the Natriuretic Response Prediction Equation using a Race-free Estimated Glomerular Filtration Rate Equation. Journal Of Cardiac Failure 2025 PMID: 40441408, DOI: 10.1016/j.cardfail.2025.05.013.Peer-Reviewed Original ResearchCitationsSerum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study
Núñez J, Miñana G, Villalonga M, Asenjo M, Carrera M, Epelde F, Gil M, Chivite D, Contra A, Pla X, Casado J, Miró Ò, de la Espriella R, Testani J, Trullàs J. Serum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study. Internal And Emergency Medicine 2025, 20: 1399-1409. PMID: 40379935, DOI: 10.1007/s11739-025-03961-z.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAcute heart failureHeart failureDiuretic responseSerum chlorideThiazide diureticsWeight lossAssociated with smaller weight lossPatients admitted with acute heart failurePathophysiology of heart failureIn-hospital weight lossAssociated with higher weight lossObservational cohort studyDiuretic resistanceHF prognosisThiazideCohort studyDiureticsPatientsHyperchloraemiaOverall populationHypochloraemiaClinical sitesSerumSmall weight lossFailureDecongestion in heart failure: medical and device therapies
Cox Z, Damman K, Testani J. Decongestion in heart failure: medical and device therapies. Nature Reviews Cardiology 2025, 1-17. PMID: 40295876, DOI: 10.1038/s41569-025-01152-z.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHeart failure symptomsHeart failureDevice therapyFailure symptomsPersistent heart failure symptomsDesign of clinical trialsImplementing novel therapiesHeart failure outcomesMagnitude of benefitImprove decongestionPrimary therapyLoop diureticsResidual congestionNovel therapiesAdverse outcomesClinical trialsTherapyMedical strategiesPredominant causeFailure outcomesHospital readmissionHospitalTargeting congestionDecongestionHeart
Clinical Trials
Current Trials
Mechanisms of Diuretic Resistance in Heart Failure (MsDR)
HIC ID2000032328RolePrincipal InvestigatorPrimary Completion Date03/31/2028Recruiting ParticipantsGenderBothAge18+ yearsErtugliflozin in Acute Heart Failure
HIC ID2000027951RolePrincipal InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Copy Link
Activities
activity NIH/NHLBI Loan Repayment Program
03/04/2022 - PresentPeer Review Groups and Grant Study SectionsRevieweractivity Journal of the Society for Cardiovascular Angiography and Interventions
2022 - PresentJournal ServiceEditorial Board MemberDetailsEditorial Boardactivity Journal of The American College of Cardiology Heart Failure
02/14/2022 - PresentJournal ServiceEditorDetailsSection Editor of the Kidney in Heart Failure Sectionactivity Reprieve cardiovascualr
09/01/2020 - PresentAdvisory BoardsAdvisorDetailsReprieve CardiovascularClinical trial steering committeeactivity Boehringer Ingelheim
2019 - PresentAdvisory BoardsAdvisorDetailsBoehringer IngelheimEmpagliflozin Scientific Advisory Board
Clinical Care
Copy Link
Overview
Jeffrey Testani, MD, MTR (master of science in translational research) is a cardiologist who specializes in advanced heart failure. People with advanced heart failure experience shortness of breath and other symptoms even while at rest despite conventional therapies and strategies.
Dr. Testani’s work focuses on the connections between fluid build-up and heart failure. When the heart is unable to pump an adequate supply of blood to the body, the kidneys respond by increasing the volume of fluids. Dr. Testani and fellow researchers have determined that a diabetes medication can reduce fluid build-up in diabetic patients with heart failure.
Dr. Tetany’s current research involves studying hundreds of heart patients, producing 500,000 biospecimens, or samples, that can be used to determine specific paths and characteristics that lead to heart failure.
Dr. Testani is an associate professor of medicine (cardiology) at Yale School of Medicine.
Clinical Specialties
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- February 10, 2025
New Professors in the Department of Internal Medicine
- October 25, 2024
Can a ‘Kidney Action Team’ Improve Patient Outcomes?
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- February 26, 2024
Reanalyzing the Impact of COVID-19 on the Kidneys
Get In Touch
Copy Link
Contacts
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.